Literature DB >> 21544532

Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.

Francesco M Minuto1, Eugenia Resmini, Mara Boschetti, Alberto Rebora, Laura Fazzuoli, Marica Arvigo, Massimo Giusti, Diego Ferone.   

Abstract

The objective of this study is to assess the secretory pattern of GH after Oral Glucose Tolerance Test (OGTT) or day-curve (DC), in relation with IGF-I and to evaluate the influence of therapy on OGTT. A retrospective analysis in 279 OGTTs performed in 93 acromegalic patients in our unit from January 1988 to December 2005, in 77 patients also DC data were retrived. GH concentration was evaluated by 3 different systems (RIA, IRMA and chemiluminescence assays), and IGF-I by two RIAs. About 12% of OGTT samples were discordant with the baseline, while discordance between nadir and 120th minute was much lower (5%), with all discordant values, except one, near the cut-off lines. Correlation between DC and OGTT data was around 0.99 among all values, discordance rate between nadir and minimum DC was much lower than that with mean DC. In almost 80% of cases there was a complete concordance between OGTT and DC results, and in about 30% IGF-I was discordant with GH. Correlation analysis between IGF-I and GH was highest with DC data and lowest with OGTT baseline (T0). Considering different treatments discrepancy rates between GH and IGF-I were comparable. The best GH parameter is the minimum GH DC, although in the clinical practice the evaluation of OGTT GH in association with IGF-I is the most practical approach. In this case, the basal and T120 GH values can replace multiple sampling. Different treatment modalities do not influence the discordance rate between GH and IGF-I.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21544532     DOI: 10.1007/s11102-011-0313-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  23 in total

Review 1.  Editorial: acromegaly--consensus, what consensus?

Authors:  Peter J Trainer
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

2.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

3.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

4.  Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.

Authors:  A L Barkan; I Z Beitins; R P Kelch
Journal:  J Clin Endocrinol Metab       Date:  1988-07       Impact factor: 5.958

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 6.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 7.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

8.  Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly.

Authors:  A Barreca; E Ciccarelli; F Minuto; P Bruzzi; G Giordano; F Camanni
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05

9.  Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

Authors:  Robert D Murray; Kiwon Kim; Song-Guang Ren; Marjorie Chelly; Yutaka Umehara; Shlomo Melmed
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 10.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

View more
  4 in total

1.  Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

Authors:  Jessica A Brzana; Chris G Yedinak; Johnny B Delashaw; Hume S Gultelkin; David Cook; Maria Fleseriu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 2.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 3.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

4.  Prevalence of acromegaly in patients with symptoms of sleep apnea.

Authors:  Gemma Sesmilo; Eugenia Resmini; Marcel Sambo; Concepción Blanco; Fernando Calvo; Fernando Pazos; Pablo Fernández-Catalina; Purificación Martínez de Icaya; Concepción Páramo; Carmen Fajardo; Mónica Marazuela; Cristina Álvarez-Escolá; Juan Jose Díez; Verónica Perea
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.